Weekly Analysts’ Ratings Changes for Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals (NASDAQ: APLS) recently received a number of ratings updates from brokerages and research firms:

• 11/4/2024 – Apellis Pharmaceuticals had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $25.00 price target on the stock.
• 10/31/2024 – Apellis Pharmaceuticals was upgraded by analysts at Evercore ISI to a “strong-buy” rating.
• 10/25/2024 – Apellis Pharmaceuticals is now covered by analysts at Royal Bank of Canada. They set a “sector perform” rating and a $25.00 price target on the stock.
• 10/24/2024 – Apellis Pharmaceuticals had its price target lowered by analysts at Mizuho from $39.00 to $38.00. They now have a “neutral” rating on the stock.
• 10/16/2024 – Apellis Pharmaceuticals is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $35.00 price target on the stock.
• 10/16/2024 – Apellis Pharmaceuticals is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 9/24/2024 – Apellis Pharmaceuticals had its price target lowered by analysts at Wells Fargo & Company from $47.00 to $43.00. They now have an “equal weight” rating on the stock.
• 9/23/2024 – Apellis Pharmaceuticals had its price target lowered by analysts at Robert W. Baird from $96.00 to $92.00. They now have an “outperform” rating on the stock.
• 9/20/2024 – Apellis Pharmaceuticals had its price target lowered by analysts at Mizuho from $42.00 to $39.00. They now have a “neutral” rating on the stock.
• 9/20/2024 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
• 9/13/2024 – Apellis Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $64.00 to $57.00. They now have an “overweight” rating on the stock.

Apellis Pharmaceuticals Price Performance

Shares of APLS stock traded up $0.58 during trading hours on Monday, reaching $28.56. The company had a trading volume of 8,006,241 shares, compared to its average volume of 1,723,614. Apellis Pharmaceuticals, Inc. has a 12-month low of $26.28 and a 12-month high of $73.80. The company has a market capitalization of $3.48 billion, a price-to-earnings ratio of -10.42 and a beta of 0.87. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08. The stock has a fifty day moving average of $32.04 and a 200-day moving average of $37.53.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $199.70 million during the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. Apellis Pharmaceuticals’s quarterly revenue was up 110.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.02) earnings per share. On average, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.4 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently bought and sold shares of APLS. Capital Performance Advisors LLP acquired a new position in Apellis Pharmaceuticals during the 3rd quarter worth $56,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Apellis Pharmaceuticals during the first quarter worth approximately $89,000. nVerses Capital LLC raised its holdings in Apellis Pharmaceuticals by 300.0% in the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after acquiring an additional 2,100 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after acquiring an additional 781 shares during the last quarter. Finally, CWM LLC grew its holdings in Apellis Pharmaceuticals by 299.9% during the 2nd quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after acquiring an additional 3,113 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).